Simon Joel
Overview
Explore the profile of Simon Joel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iyengar S, Ariza-McNaughton L, Clear A, Taussig D, Auer R, Roe A, et al.
Br J Haematol
. 2015 Jul;
173(1):165-9.
PMID: 26215849
No abstract available.
2.
Ghazaly E, Perry J, Kitromilidou C, Powles T, Joel S
J Chromatogr B Analyt Technol Biomed Life Sci
. 2014 Sep;
969:213-8.
PMID: 25195021
A simple and rapid ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry (UPLC-MS/MS) method has been developed for measuring intracellular concentrations of the anticancer agent 7-ethyl-10-hydroxycamptothecin (SN-38) in tumour cells using camptothecin...
3.
Casado P, Alcolea M, Iorio F, Rodriguez-Prados J, Vanhaesebroeck B, Saez-Rodriguez J, et al.
Genome Biol
. 2013 May;
14(4):R37.
PMID: 23628362
Background: Tumor classification based on their predicted responses to kinase inhibitors is a major goal for advancing targeted personalized therapies. Here, we used a phosphoproteomic approach to investigate biological heterogeneity...
4.
Casado P, Rodriguez-Prados J, Cosulich S, Guichard S, Vanhaesebroeck B, Joel S, et al.
Sci Signal
. 2013 Mar;
6(268):rs6.
PMID: 23532336
Kinases determine the phenotypes of many cancer cells, but the frequency with which individual kinases are activated in primary tumors remains largely unknown. We used a computational approach, termed kinase-substrate...
5.
Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al.
Blood
. 2013 Jan;
121(12):2274-84.
PMID: 23341541
Phosphoinositide-3 kinase (PI3K) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis, but early-phase studies of the PI3K p110δ inhibitor GS-1101 have reported inferior responses in MCL compared with other...
6.
Popat R, Maharaj L, Oakervee H, Cavenagh J, Joel S
Br J Haematol
. 2012 Oct;
160(1):111-4.
PMID: 23078038
No abstract available.
7.
Gretton S, Ross J, Rutter D, Sato H, Droney J, Welsh K, et al.
J Pain Symptom Manage
. 2012 Sep;
45(4):670-80.
PMID: 22995672
Context: Morphine is the opioid of choice for cancer-related pain, but for many patients the benefits of morphine are outweighed by its side effect profile. Morphine is metabolized to morphine-3-glucuronide...
8.
Stevens J, Waters R, Sieniawska C, Kassam S, Montoto S, Fitzgibbon J, et al.
Br J Haematol
. 2011 Jul;
154(4):448-56.
PMID: 21770918
We have previously reported presentation serum selenium level to be predictive of outcome in diffuse large B-cell lymphoma. This has now been studied in a further 430 patients, 163 with...
9.
Perry J, Ghazaly E, Kitromilidou C, McGrowder E, Joel S, Powles T
Mol Cancer Ther
. 2010 Oct;
9(12):3322-9.
PMID: 20889729
Lapatinib is a specific HER1 and 2 targeted tyrosine kinase inhibitor now widely used in combination with chemotherapy in the clinical setting. In this work, we investigated the interactions between...
10.
Streetly M, Maharaj L, Joel S, Schey S, Gribben J, Cotter F
Blood
. 2010 Mar;
115(19):3939-48.
PMID: 20190189
GCS-100 is a galectin-3 antagonist with an acceptable human safety profile that has been demonstrated to have an antimyeloma effect in the context of bortezomib resistance. In the present study,...